#DLBCL
In this paper, the authors report a 46.2% response rate with zanubrutinib alone in CD79B-mutated relapsed or refractory #DLBCL. Findings from this single-arm phase 2 study support further research in selected patients. Delve deeper: 📰https://hsphere.pub/uiq
November 16, 2026 at 2:05 PM
RR DLBCL treatment choices: CAR T or bispecific antibodies?

Drs. Joshua Brody and Jeremy Abramson weigh in on SOHO Spotlight.
🎧 soho.click/soho-spotlig... #DLBCL #HemOnc
November 13, 2026 at 2:03 PM
⚛️ Rocbrutinib + R-CHOP elicited responses in non-GCB DLBCL and MCL, according to new data from a phase 1b study presented at #ESMO26

Read more here 📰: www.onclive.com/view/rocbrut...

#oncology #lymsm
Rocbrutinib Plus R-CHOP Elicits Responses in Previously Untreated B-Cell Lymphomas | OncLive
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
www.onclive.com
November 4, 2026 at 8:18 PM
Actinium further announces 3 ASH abstracts for Iomab-ACT in CAR T therapy & sickle cell disease
*1st results of Iomab-ACT as conditioning in SCD
*Low dose Iomab-ACT for r/r DLBCL & B-cell ALL
*Iomab-ACT conditioning before CD19-directed CAR T-cell therapy
#$ATNM
ir.actiniumpharma.com/press-releas...
November 4, 2026 at 6:38 PM
🔬 ESH Session IV: DLBCL, all case-based.
Bjoern Chapuy on elderly patients: first, do no harm.
Maria Gomes da Silva on first line DLBCL, including pitfalls like CNS prophylaxis and double-hit lymphoma. 🧵

#ESHLYMPHOMA2026 #ESHCONFERENCES #LYMsm #Lmsm #ESHELEARNING
October 30, 2026 at 11:38 AM
Every patient with RR DLBCL deserves a CAR T discussion. Drs. Joshua Brody and Jeremy Abramson explain why on SOHO Spotlight.

🎧 soho.click/soho-spotlig... #CARTcell #HemOnc
October 30, 2026 at 1:04 PM
🔄 Marek Trněný: in R/R DLBCL, novel therapies (mainly T-cell engagers) improve survival; biopsy and sequencing matter.
🎤 Gloria Iacoboni: from transplant-eligible to CAR-T-eligible; CAR-T still favored over bispecifics in R/R LBCL.

#ESHLYMPHOMA2026 #ESHCONFERENCES #LYMsm #Lmsm #ESHELEARNING
October 30, 2026 at 11:38 AM
#$ADCT Tanabe filed ZYNLONTA in Japan for r/r DLBCL + Nippon Shinyaku sublicense (filing, not approval).
Hub: www.merlintrader.com/adc-therapeu...
Chart: justcharts.merlintrader.com#ADCT
NFA
October 29, 2026 at 2:27 PM
#$ADCT Tanabe filed ZYNLONTA in Japan for r/r DLBCL + Nippon Shinyaku sublicense (filing, not approval).
Hub: www.merlintrader.com/adc-therapeu...
Chart: justcharts.merlintrader.com#ADCT
NFA
October 29, 2026 at 2:27 PM
Positive Predictive Value of [18F]FDG PET/CT for the Detection of Bone Marrow Infiltration in Diffuse Large B-Cell Lymphoma: Impact of Focal versus Diffuse Pattern

Bone marrow involvement in diffuse large…

📄 PDF: sjoranm.com/sjoranm/article/download/130/104

#SJORANM #Radiology #NuclearMedicine
Positive Predictive Value of [18F]FDG PET/CT for the Detection of Bone Marrow Infiltration in Diffuse Large B-Cell Lymphoma: Impact of Focal versus Diffuse Pattern
Swiss J. Radiol. Nucl. Med. · Vol. 30 No. 2 · 2026-05-30 · DOI doi.org/10.59667/sjoranm.v30i2.14 · Bone marrow involvement in diffuse large B-cell lymphoma (DLBCL) is a major prognostic factor corresponding to Ann Arbor stage IV disease. While [18F]FDG PET/CT has largely replaced bone marrow…
sjoranm.com
October 29, 2026 at 1:50 AM
#CLRB Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DL…

https://www.stocktitan.net/news/CLRB/cellectar-biosciences-reports-case-study-highlighting-complete-1utbiitage9y.html?utm_source=stocktitan-bluesky&utm_medium=social
Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
Cellectar Biosciences (CLRB) reported a complete response lasting more than eight years in one heavily pretreated lymphoma patient given iopofosine I 131. The patient had diffuse large B-cell lymphoma (DLBCL), four prior treatment lines and a stem cell transplant. After a single dose, she achieved complete response by Day 85; as of May 2026, she had no disease progression and needed no additional anticancer therapy. Blood-related toxicities resolved.Cellectar expects patient dosing in its confirmatory Phase 3 Waldenström macroglobulinemia study to begin in the first quarter of 2027 and plans an FDA accelerated approval application in the first half of 2027.
www.stocktitan.net
October 27, 2026 at 11:15 AM
How is immunotherapy transforming care in relapsed DLBCL? Hear from the experts in this SOHO Spotlight clip. 🎧 soho.click/soho-spotlig...
#DLBCL #lymsm #Immunotherapy
October 23, 2026 at 1:31 PM
🔬 Could miR-155 help improve diagnosis of DLBCL?
This review explores how miR-155 influences lymphoma pathogenesis, immune responses and the tumor microenvironment—and its potential as a diagnostic, prognostic or predictive biomarker. #DLBCL #Lymphoma
mdpi.com/2227-9059/12...
October 23, 2026 at 7:54 AM
The authors included RRIDs in their in Blood Neoplasia paper! We value the author's support of reproducibility. #ReproducibleResearch #BetterScience #STMpublishing
Unmasking BCL2A1: IL10/STAT3-Driven BCL2A1 Expression Promotes Apoptosis Resistance in DLBCL
Read the full paper: Unmasking BCL2A1: IL10/STAT3-Driven BCL2A1 Expression Promotes Apoptosis Resistance in DLBCL
doi.org
October 23, 2026 at 7:00 AM
lncRNA CHROMR promotes DLBCL viability and invasion in an m 6A-dependent manner

Acta biochimica et biophysica Sinica · Liu et al.
doi.org/10.3724/abbs.2026151
#RNAsky #RNAmods
lncRNA CHROMR promotes DLBCL viability and invasion in an m 6A-dependent manner
Acta biochimica et biophysica Sinica · Liu C, Wu M, Zhang C, Zhao Y, Du Y, Hou J, Gao R, Yang K, Li F, Guan T, Zhang H, Yu B.
doi.org
October 21, 2026 at 5:58 PM
Relapsed or refractory #DLBCL remains difficult to treat after multiple therapies.
A phase 2 study found that dual #HDAC/PI3Kα inhibition with ifupinostat produced clinical responses, alongside substantial hematologic toxicity.
#STTT #OpenAccess: doi.org/10.1038/s413...
October 21, 2026 at 12:45 PM
Bispecifics, ADCs, or a combination? Dr.Joshua Brody and Dr. Jeremy Abramson cover how to choose second-line therapy for #DLBCL, especially when CAR T isn’t an option. Ep. 2 is out now: soho.click/soho-spotlig...
October 20, 2026 at 10:18 PM
Breakthrough in Cancer Treatment: Epcoritamab and R-CHOP Show Strong Results Against DLBCL#USA#AbbVie#North_Chicago#DLBCL#Genmab
Breakthrough in Cancer Treatment: Epcoritamab and R-CHOP Show Strong Results Against DLBCL
AbbVie and Genmab report improved progression-free survival in DLBCL patients with their new treatment regimen combining Epcoritamab and R-CHOP, marking a significant advancement in cancer therapy.
third-news.com
October 20, 2026 at 5:31 AM
新たな標準治療の可能性!DLBCL患者へのエプコリタマブとR-CHOP併用療法の試験成果#エプコリタマブ#R-CHOP#DLBCL

初発のびまん性大細胞型B細胞リンパ腫(DLBCL)患者を対象にしたEPCORE DLBCL-2試験で、エプコリタマブとR-CHOP併用療法が無増悪生存期間を有意に改善したことが明らかになりました。
新たな標準治療の可能性!DLBCL患者へのエプコリタマブとR-CHOP併用療法の試験成果
初発のびまん性大細胞型B細胞リンパ腫(DLBCL)患者を対象にしたEPCORE DLBCL-2試験で、エプコリタマブとR-CHOP併用療法が無増悪生存期間を有意に改善したことが明らかになりました。
tokyo.publishing.3rd-in.co.jp
October 20, 2026 at 5:34 AM
Norway’s first-line polatuzumab decision turns on a new price offer—and POLARIX survival extrapolation. https://www.mattheneus.com/editorial/norway-polatuzumab-dlbcl-new-price-access-polarix-survival-extrapolation-2026-10-19 #HTA #HealthEconomics #RegulatoryAffairs
October 20, 2026 at 11:05 AM
New episode drops Monday! 🎙️ Drs. Brody and Abramson take on a tough R/R DLBCL case: fixed-duration options, bispecifics vs. ADCs, MRD monitoring, and practical tips for community oncologists.

Launches 10/19. Subscribe at soho.click/spotlightpod...
October 15, 2026 at 3:36 PM
Two frontline-changing readouts in one week (ATOMIC in dMMR colon cancer and epcoritamab plus R-CHOP in DLBCL) is a lot to absorb. If it helps, MeDucation's podcast station turns weeks like this into something to listen to on the drive in.
October 14, 2026 at 5:42 PM
Last week’s #OncFive:
✅ Atezolizumab approved for CRC #crcsm #oncology
🎗️ Tucatinib approved for breast cancer #bcsm
🩸 IberDd hits PFS in myeloma #mmsm #hematology
🔵 Fast track for VIR-5500 in mCRPC #pcsm
🩸 Epcoritamab+R-CHOP hits PFS in DLBCL #lymsm

www.onclive.com/view/the-onc...
The OncFive: Top Oncology Articles for the Week of 10/4/2026 | OncLive
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
www.onclive.com
October 11, 2026 at 12:27 PM